Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 2

Средства доставки препаратов для больных хронической обструктивной болезнью легких
В.В. Архипов

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD, 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf Accessed 2019 Oct 24.
2. Hakim A, Usmani OS. Structure of the lower respiratory tract. In: Reference module in biomedical sciences. Elsevier; 2014.
3. Bisgaard H, O’Callaghan C, Smaldone GC. Drug delivery to the lung. New York; Basel: CRC Press; 2001. 536 p.
4. Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidisciplinary Respiratory Medicine 2015 Apr;10(1):13.
5. Stein SW. Estimating the number of droplets and drug particles emitted from MDIs. AAPS PharmSciTech 2008;9(1):112-5.
6. Dolovich M. New delivery systems and propellants. Canadian Respiratory Journal 1999 May-Jun;6(3):290-5.
7. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Archives of Disease in Childhood 1990 Mar;65(3):308-10.
8. Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2015 Dec;28(6):474-85.
9. van der Palen J. Peak inspiratory flow through diskus and turbuhaler, measured by means of a peak inspiratory flow meter (In-Check DIAL). Respiratory Medicine 2003 Mar;97(3):285-9.
10. Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Current Medical Research and Opinion 2010 Nov;26(11):2527-33.
11. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. The European Respiratory Journal 1997 Sep;10(9):2105-9.
12. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:353-63.
13. Alaboud SS. In-vitro inhalation performance for formoterol dry powder and metred dose inhalers. In-vitro characteristics of the emitted dose from the formoterol dry powder and metred dose inhalers to identify the influence of inhalation flow, inhalation volume and the number of inhalation per dose [PhD dissertation]. Bradford: University of Bradford; 2011. 321 p.
14. Newman SP, Clarke SW. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest 1993 May;103(5):1442-6.
15. Iwanaga T, Tohda Y, Nakamura S, Suga Y. The Respimat® Soft Mist inhaler: implications of drug delivery characteristics for patients. Clinical Drug Investigation 2019 Nov;39(11):1021-30.
16. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. The European Respiratory Journal 2011 Jun;37(6):1308-31.
17. Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, Meyer T, Rabe KF, Magnussen H, Watz H. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2015 Aug 1;192(3):295-306.
18. Kabitz HJ, Walterspacher S, Walker D, Windisch W. Inspiratory muscle strength in chronic obstructive pulmonary disease depending on disease severity. Clinical Science 2007 Sep;113(5):243-9.
19. Janssens W, VandenBrande P, Hardeman E, De Langhe E, Philps T, Troosters T, Decramer M. Inspiratory flow rates at different levels of resistance in elderly COPD patients. The European Respiratory Journal 2008 Jan;31(1):78-83.
20. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age and Ageing 2007 Mar;36(2):213-8.
21. Al-Showair RA, Pearson SB, Chrystyn H. The potential of a 2Tone Trainer to help patients use their metered-dose inhalers. Chest 2007 Jun;131(6):1776-82.
22. Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, MacHale E, Mokoka M, Moran CN, Sartini Bhreathnach A, MacHale P, Tappuni S, Deering B, Jackson M, McCarthy H, Mellon L, Doyle F, Boland F, Reilly RB, Costello RW. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 2017 May;195(10):1333-43.
23. Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 2018 Apr;5(2):111-23.
24. Ciciliani A, Wachtel H, Heussel C, Langguth P. Evaluation of Respimat® Soft Mist™ inhaler based on in vitro measurements and CFD simulations. Respiratory Drug Delivery Europe 2015;2:367-62.
25. Ciciliani A, Wachtel H, Langguth P. Comparing Respimat® Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respiratory Drug Delivery 2014;2:453-6.
26. Erdélyi T, Lázár Z, Odler B, Bohács A, Eszes N, Jókay A, Farkas Á, Balásházy I, Müller V. Reproducibility of inhaler use and pulmonary drug deposition in COPD. European Respiratory Journal 2016;48:PA960.
27. Barczok M, Perleberg C, Kardos P, Hodder R. Presented at VIII Deutsches Aerosol Therapie Seminar, 2003 November, Marburg, Germany.
28. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. International Journal of Chronic Obstructive Pulmonary Disease 2008;3(4):763-70.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]